Binaytara Foundation Hosted Seattle Cellular Therapy Summit

Hematologists & Oncologists from Across Country Met to Discuss Latest Updates in Care

 

On August 4-5, 2023, the Binaytara Foundation held the Seattle Cellular Therapy Summit. This annual conference gathers leading experts to present the latest treatments and practice-changing updates in care.

 

Drs. Mazyar Shadman and Krish Patel, of the University of Washington/Fred Hutchinson and Swedish Cancer Institute, respectively, led the meeting, providing practice-changing information to around 100 attendees. Session topics included Updates on Approved CAR-T Cell Therapies, Addressing Barriers to Cellular Therapy, and Debates on Myeloma & MCL.

“Dr. Shadman, Dr. Shah, and I, with the help of the Foundation, put together this meeting with wonderful faculty experts from around the country who are the leaders in cellular therapy. We are thrilled to have this inaugural conference in Seattle, and we hope for this conference to be an annual meeting. It’s been a joy to work with the Binaytara Foundation towards this goal.” Dr. Patel explained.

 

The meeting featured faculty from City of Hope, Moffitt Cancer Center, University of Washington, Fred Hutch, Providence, University of Nebraska, Mayo Clinic, and MD Anderson Cancer Center.

 

“This meeting has brought together experts from across the country interested in adaptive cellular immunotherapies. I am very impressed with what the Foundation is doing in global health, understanding disparities, and advancing education in cancer care across the spectrum. I am thrilled to be here. It was lovely to see the perspectives, debates, and interactions among faculty today discussing cutting-edge adaptive T-cell therapies, including CAR-T therapies.” Dr. Krishna Komanduri, Dr. Krishna Komanduri, Physician in-chief at the UCSF Hellen Diller Family Comprehensive Cancer Center, shared.

 

We thank the conference co-chairs, faculty, BTF staff, and volunteers for an amazing conference. We look forward to next year!

Staff Writer - The Cancer News

Recent Posts

ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC)

By: Tiantian Zhang1, Yiqun Han2, Lei Deng3 1. Department of Internal Medicine, University of Central…

5 months ago

ASCO24 LAURA Trial Summary

By: Zhiting Tang1, Lei Deng21. Unity Hospital, Rochester Regional Health, Rochester, NY2. University of Washington/Fred…

5 months ago

FDA Approves Tovorafenib for Pediatric Low-Grade Glioma With BRAF Mutation

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug…

6 months ago

FDA Approves Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 29, 2024, the U.S. Food and Drug…

6 months ago

FDA Approves Lutetium Lu 177 Dotatate for SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug…

6 months ago

FDA Approves Alectinib for Adjuvant Treatment in Non-Small Cell Lung Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 18, 2024, the U.S. Food and Drug…

6 months ago